2011
DOI: 10.1093/anatox/35.7.431
|View full text |Cite
|
Sign up to set email alerts
|

Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations

Abstract: Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
12
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 36 publications
0
12
0
Order By: Relevance
“…These genes are characterized by significant genetic variability causing inter-individual differences in required dose, drug response and side effects [5][6][7][8].…”
Section: Introductionmentioning
confidence: 99%
“…These genes are characterized by significant genetic variability causing inter-individual differences in required dose, drug response and side effects [5][6][7][8].…”
Section: Introductionmentioning
confidence: 99%
“…Previous association studies have produced mixed results regarding OPRM1 polymorphisms and methadone treatment efficacy, and side effects included changes in libido and insomnia [ 24 ], in MMT response status in terms of illicit opioid use detection in random urinalysis [ 25 ], in apparent susceptibility to methadone poisoning [ 26 , 27 ], and in both pain responses and opioid addiction [ 23 ]. Among studies that focused on genetic polymorphisms related to pharmacodynamics of methadone, only one study investigated the association between the noted sleep problems of opioid-addicted individuals and polymorphisms in gene coding for the OPRM1 [ 24 ]; unfortunately the role of the OPRM1 individual’s pair of haplotypes (diplotype) remains uncertain because they did not consider analysis of OPRM1 diplotypes.…”
Section: Discussionmentioning
confidence: 99%
“…Most of the current applicable studies and results on PGx of pain relievers are focused on single candidate gene examples [36][37][38][39]. However, with advances in genome wide association studies [40], reduction of technology costs in whole genome sequencing/analyses, and larger numbers of trained health care professionals working in this area, new research will lead to a better understanding and characterization of genomic determinants underlying addiction behavior.…”
Section: Researchmentioning
confidence: 99%